Aytu BioPharma Q3 Revenue Falls to $12.4M, Posts $5.6M Net Loss; EXXUA Launch Shows Early Traction
AYTU sits 79% above its 52-week low of $1.26 on elevated volume (2.0× avg).
Summary
Aytu BioPharma reported fiscal third-quarter 2026 net revenue of $12.4 million, a significant decrease from $18.5 million in the prior year, and posted a net loss of $5.6 million compared to net income of $4.0 million in Q3 fiscal 2025. Adjusted EBITDA also turned negative at $(2.8) million. The company's new product, EXXUA, contributed $2.4 million in net revenue during its partial launch quarter, with management highlighting encouraging early traction, including over 1,300 prescriptions written by more than 450 unique prescribers. The decline in overall revenue was primarily attributed to a strategic shift of sales force prioritization towards EXXUA and increased generic competition for its legacy ADHD portfolio. The company ended the quarter with $26.7 million in cash. Traders will be closely watching the continued ramp-up of EXXUA sales to offset the declines in the legacy business and improve overall profitability.
At the time of this announcement, AYTU was trading at $2.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $1.26 to $3.07. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Access Newswire.